Ligand Pharmaceuticals Inc. is an early-stage biotechnology company, focused on discovering and developing new drugs that address critical unmet medical needs in the areas of thrombocytopenia, cancer, hepatitis C, hormone-related diseases, osteoporosis and inflammatory diseases. The company strives to develop drugs that are more effective and/or safer than existing therapies, that are more ...
more
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of novel therapeutics for cancer and viral diseases. It develops a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase I clinical trial for the treatment of solid cancers, as ...
more
Alliqua, Inc., a biomedical products company, through its subsidiaries, focuses on the development and manufacture of proprietary technologies in the fields of drug delivery, advanced wound care, and liver health preservation. The company intends to develop, manufacture, and market active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel ...
more
Aradigm Corp. is a developer of innovative drug delivery systems that enable patients to self-administer liquid drugs that would otherwise be given by injection. The company's hand-held AERx delivery system is designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds either to the lungs for respiratory conditions or through the lung to ...
more
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer by regulating cell signaling with small molecules in the United States. Its lead cancer product candidate, AP23573, is an mTOR inhibitor for the treatment of solid tumors, including sarcomas, hormone refractory prostate cancer, and endometrial cancer. AP23573 is in multiple Phase II ...
more
Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company, focused on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The companyÂ’'s lead drug candidates include SP-304, a guanylyl cyclase C (GC-C) receptor agonist for the treatment of chronic constipation and ...
more
We are a development stage pharmaceutical company that seeks to acquire and develop innovative products for the treatment of a variety of human diseases. Our strategy is to develop technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Specifically, we are developing prescription products for multiple ...
more
Generex Biotechnology Corporation engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. The company’s primary product, Oral-lyn is an insulin spray formulation used ...
more
Lpath, Inc. engages in the discovery and development of lipidomic-based therapeutics to treat human diseases in the United States. The companyÂ’'s product candidates include ASONEP, a humanized monoclonal antibody against sphingosine-1-phosphate, which completed phase I trials for the treatment of cancer, as well as in development stage for the treatment of multiple sclerosis, ...
more
PolyMedix, Inc. is a development stage biotechnology company and focuses on treating acute cardiovascular disorders and infectious diseases with synthetic small molecule compounds that mimic the activity of large natural protein molecules. The company, using its proprietary computational drug design technology, created heparin antagonist compounds, defensin mimetic antibiotic compounds, and ...
more
Searchlight Minerals Corp., an exploration stage company, engages in the exploration, acquisition, and development of mining and mineral properties, as well as in slag reprocessing projects. It holds interest in the Clarkdale slag project, located in Clarkdale, Arizona, which is a reclamation project to recover precious and base metals from the reprocessing of slag produced from the ...
more
SuperGen, Inc., a pharmaceutical company, engages in the discovery, acquisition, development, and commercialization of therapies for solid tumors, hematological malignancies, and blood disorders. It offers Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand ...
more
TRANSGENOMIC is a global biotechnology company providing products and services for automated high sensitivity genetic variation and mutation analysis. The company's offering includes systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.
moreZymoGenetics, Inc. engages in the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases in the areas of hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its preclinical stage internal products include IL-31, for the treatment of atopic dermatitis and inflammatory diseases. The company's phase II ...
more
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of technology and potential drugs to treat antibody-mediated diseases. It is developing Riquent as a treatment for Lupus nephritis, which is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The company was founded in 1989 and is ...
more
